GenoRate: using AI to speed up the drug development process

It can take up to 15 years and about $2.5 billion to develop a new drug treatment, so anything with the potential to shorten this cycle is going to pique the interest of the pharma sector worldwide.

Read More
Open Orphan Signs Strategic Collaboration Agreement with Empiric Logic

Open Orphan, a European-focused, rare and orphan drug consulting services platform, today announced it has signed a new strategic collaboration agreement ('the Collaboration') with Empiric Logic to build on the earlier work performed by Open Orphan and complete the build out of Open Orphan's Health Data platform, Europe's first rare disease, advocacy-led genomic database.

Read More
Open Orphan signs deal with Empiric Logic to complete Health Data platform

Europe-focussed rare and orphan drug consulting services platform provider Open Orphan has signed a new strategic collaboration agreement with Empiric Logic, it announced on Tuesday, to build on the earlier work it had performed, and complete the build out of its ‘Health Data’ platform as Europe's first rare disease, advocacy-led genomic database.

Read More
Open Orphan inks software deal

The company will include Empiric's privacy-preserving and artificial intelligence-enabled software in its rare disease database Orphan drugs treat rare diseases and address unmet medical needs Open Orphan Plc (LON:ORPH) said it has taken an 'exciting step' towards the completion of it Genomic Health Data Platform following a tie-up with a firm called Empiric Logic.

Read More